Brodsky & Smith LLC has launched investigations into whether the boards of ADT Inc., RXO Inc., PTC Inc., and Lifecore Biomedical breached their fiduciary duties by potentially failing to ensure fair processes and fair value in their respective merger agreements. ADT is being acquired by Thrive Holdings for $10 per share, RXO by C.H. Robinson for $30.25 per share in stock and cash, PTC by Schneider Electric for $205 per share in cash, and Lifecore Biomedical by Webster Equity Partners for $6.28 per share plus contingent rights. These investigations aim to protect shareholders' interests and assess if the deals offer fair value. Investors holding shares in these companies are encouraged to contact Brodsky & Smith for more information. This scrutiny could impact the finalization of these mergers.
The investigation news comes as ADT trades very close to its 52-week high of $9.93, currently at $9.90 on Pluang as of Nov 11, 2026 23:21 WIB, showing a slight 0.05% increase in the last day. This price contrasts sharply with its 52-week low of $6.08, highlighting a strong recovery. Investors on Pluang hold ADT shares for an average of 59 days and show full buying interest with 100% buy orders at this time.
